Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an announcement.
Lumos Diagnostics has issued a total of 5,228,863 new fully paid ordinary shares following the exercise of unquoted options by Lind Global Fund II and a company employee, with the shares issued without a prospectus under relevant Corporations Act provisions. In a cleansing notice to the market, the company confirmed it remains compliant with its continuous disclosure and financial reporting obligations, stated there is no excluded information that must be disclosed ahead of its FY 2026 half-year report due by 27 February 2026, and indicated that the expected draft of that report does not contain undisclosed price-sensitive information, helping to maintain regulatory transparency for investors as its capital base modestly expands.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.31 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics is a healthcare technology company specialising in rapid, cost-effective point-of-care diagnostic test technology that supports clinicians in diagnosing and managing medical conditions. The company provides customised assay development and manufacturing services for point-of-care tests, offers proprietary digital reader platforms, and directly develops, manufactures and commercialises Lumos-branded tests targeting infectious and inflammatory diseases.
Average Trading Volume: 4,566,001
Technical Sentiment Signal: Buy
Current Market Cap: A$216.5M
See more data about LDX stock on TipRanks’ Stock Analysis page.